1-2 of 2
Michela Buscarino
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

Mariangela Russo, Giulia Siravegna, Lawrence S. Blaszkowsky, Giorgio Corti, Giovanni Crisafulli, Leanne G. Ahronian, Benedetta Mussolin, Eunice L. Kwak, Michela Buscarino, Luca Lazzari, Emanuele Valtorta, Mauro Truini, Nicholas A. Jessop, Hayley E. Robinson, Theodore S. Hong, Mari Mino-Kenudson, Federica Di Nicolantonio, Ashraf Thabet, Andrea Sartore-Bianchi, Salvatore Siena, A. John Iafrate, Alberto Bardelli, Ryan B. Corcoran
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (2): 147–153.
https://doi.org/10.1158/2159-8290.CD-15-1283
Published: 04 February 2016
View article titled, Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Open the PDF for Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Francesco Sassi, Davide Torti, Claudio Isella, Davide Corà, Federica Di Nicolantonio, Michela Buscarino, Consalvo Petti, Dario Ribero, Nadia Russolillo, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Luca Molinaro, Emanuele Valtorta, Andrea Sartore-Bianchi, Mauro Risio, Lorenzo Capussotti, Marcello Gambacorta, Salvatore Siena, Enzo Medico, Anna Sapino, Silvia Marsoni, Paolo M. Comoglio, Alberto Bardelli, Livio Trusolino
Journal: Cancer Discovery
Cancer Discov (2011) 1 (6): 508–523.
https://doi.org/10.1158/2159-8290.CD-11-0109
Published: 16 November 2011
View article titled, A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Open the PDF for A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer in another window
Includes: Supplementary data